Lisa Ebert

Research Interests

Biomarkers Cancer Therapy Cellular Immunology Tumour Immunology Cancer Biology and Clinical Oncology Immunology and Infection

APrf Lisa Ebert

Centre for Cancer Biology

College of Health

Associate Professor Lisa Ebert (B.Sc. (Hons), PhD) is a clinically-oriented cancer research scientist, with a particular interest in immunology and cancer immunotherapy. 
She completed her PhD at the University of Adelaide, before undertaking post-doctoral research at the University of Bern (Switzerland) and the Ludwig Institute for Cancer Research (Melbourne). During this time, she developed particular expertise in human immunology, cancer cell biology, multi-parameter flow cytometry and immune monitoring of cancer immunotherapy clinical trials.
Now, A/Prof Ebert is a Group Leader of Cancer Immunotherapy Research, within the Translational Oncology Laboratory at the Centre for Cancer Biology (CCB) - an alliance between UniSA and SA Pathology. Her research is aimed at understanding interactions between cancer cells and the immune system, and using this knowledge to improve cancer treatment. Key focus areas include developing new immunotherapy approaches for treating glioblastoma (brain tumours) and optimising the therapeutic efficacy of checkpoint inhibitors in melanoma. For further details on A/Prof Ebert's current research, refer to the CCB website: https://www.centreforcancerbiology.org.au/research/translational-oncology-laboratory/
A/Prof Ebert has co-authored numerous papers in the fields of immunology and cancer - click on the green ORCID ID badge to the right for details. She currently holds research grants from the NHMRC, Cancer Australia, Ray & Shirl Norman Cancer Research Trust, the Neurosurgical Research Foundation and others, and supervises several Honours, Masters and PhD students. Enquiries from prospective students are welcome.

Year Citation
2024 Revesz, I. A., Joyce, P., Ebert, L. M., & Prestidge, C. A. (2024). Effective γδ T-cell clinical therapies: current limitations and future perspectives for cancer immunotherapy. Clinical and Translational Immunology, 13(2, article no. e1492), 1-16.
DOI Scopus9 WoS9 Europe PMC7
2024 Gargett, T., Truong, N. T. H., Gardam, B., Yu, W., Ebert, L. M., Johnson, A., . . . Brown, M. P. (2024). Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers. Journal for ImmunoTherapy of Cancer, 12(5), e008659-1-e008659-17.
DOI Scopus33 WoS32 Europe PMC26
2024 Gargett, T., & Ebert, L. M. (2024). Striking an alliance between T cells and macrophages for enhanced cancer immunotherapy. Immunology & Cell Biology, 102(7), 535-537.
DOI
2024 Yu, W., Truong, N. T. H., Polara, R., Gargett, T., Tea, M. N., Pitson, S. M., . . . Brown, M. P. (2024). Endogenous bystander killing mechanisms enhance the activity of novel FAP‐specific CAR‐T cells against glioblastoma. Clinical & Translational Immunology, 13(7), e1519-1-e1519-20.
DOI Scopus10 WoS11 Europe PMC8
2024 Lertsumitkul, L., Iliopoulos, M., Wang, S. S., McArthur, S. J., Ebert, L. M., Davenport, A. J., . . . Jenkins, M. R. (2024). EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responses. Journal for ImmunoTherapy of Cancer, 12(8), e009486-1-e009486-14.
DOI Scopus10 WoS11 Europe PMC10
2023 Dmochowska, N., Milanova, V., Mukkamala, R., Chow, K. K., Pham, N. T. H., Srinivasarao, M., . . . Thierry, B. (2023). Nanoparticles Targeted to Fibroblast Activation Protein Outperform PSMA for MRI Delineation of Primary Prostate Tumors. Small, 19(21), 2204956-1-2204956-14.
DOI Scopus7 WoS7 Europe PMC8
2023 Scheer, K. G., Ebert, L. M., Samuel, M. S., Bonder, C. S., & Gomez, G. A. (2023). Bevacizumab-Induced Hypertension in Glioblastoma Patients and Its Potential as a Modulator of Treatment Response. Hypertension, 80(8), 1590-1597.
DOI Scopus10 WoS9 Europe PMC9
2023 Pickering, C., Aiyetan, P., Xu, G., Mitchell, A., Rice, R., Najjar, Y. G. G., . . . Boland, G. M. M. (2023). Plasma glycoproteomic biomarkers identify metastatic melanoma patients with reduced clinical benefit from immune checkpoint inhibitor therapy. Frontiers In Immunology, 14(1187332), 1-14.
DOI Scopus8 WoS9 Europe PMC8
2023 Kumari, S., Zemek, R. M., Palendira, U., & Ebert, L. M. (2023). Celebrating 100 years of Immunology & Cell Biology - a special focus on the field of tumor immunology in Australia. Immunology and Cell Biology, 101(9), 783-788.
DOI Scopus1 Europe PMC1
2023 Gardam, B., Gargett, T., Brown, M. P., & Ebert, L. M. (2023). Targeting the dendritic cell-T cell axis to develop effective immunotherapies for glioblastoma. Frontiers in Immunology, 14, 1261257-1-1261257-14.
DOI Scopus14 WoS13 Europe PMC12
2023 Stringer, B. W., De Silva, M. I., Greenberg, Z., Noreña Puerta, A., Adams, R., Milky, B., . . . Bardy, C. (2023). Human cerebrospinal fluid affects chemoradiotherapy sensitivities in tumor cells from patients with glioblastoma. Science Advances, 9(43), eadf1332-1-eadf1332-20.
DOI Scopus9 WoS7 Europe PMC8
2023 Myo Min, K. K., Ffrench, C. B., McClure, B. J., Ortiz, M., Dorward, E. L., Samuel, M. S., . . . Bonder, C. S. (2023). Desmoglein-2 as a cancer modulator: friend or foe?. Frontiers in Oncology, 13(1327478), 1327478-1-1327478-15.
DOI Scopus10 WoS11 Europe PMC9
2022 Ebert, L. M., Vandyke, K., Johan, M. Z., DeNichilo, M., Tan, L. Y., Myo Min, K. K., . . . Bonder, C. S. (2022). Desmoglein-2 expression is an independent predictor of poor prognosis patients with multiple myeloma. Molecular Oncology, 16(6), 1221-1240.
DOI Scopus11 WoS12 Europe PMC11
2022 Tan, L. Y., Cockshell, M. P., Moore, E., Myo Min, K. K., Ortiz, M., Johan, M. Z., . . . Bonder, C. S. (2022). Vasculogenic mimicry structures in melanoma support the recruitment of monocytes. OncoImmunology, 11(1), e2043673-1-e2043673-18.
DOI Scopus18 WoS19 Europe PMC19
2022 Kollis, P. M., Ebert, L. M., Toubia, J., Bastow, C. R., Ormsby, R. J., Poonnoose, S. I., . . . Gargett, T. (2022). Characterising Distinct Migratory Profiles of Infiltrating T-Cell Subsets in Human Glioblastoma. Frontiers in immunology, 13, 850226-1-850226-19.
DOI Scopus23 WoS21 Europe PMC18
2022 Dmochowska, N., Milanova, V., Mukkamala, R., Chow, K. K., Pham, N. T. H., Srinivasarao, M., . . . Thierry, B. (2022). Nanoparticles targeted to fibroblast activation protein outperform PSMA for MRI delineation of primary prostate tumours.
DOI
2022 Gargett, T., Ebert, L. M., Truong, N. T. H., Kollis, P. M., Sedivakova, K., Yu, W., . . . Brown, M. P. (2022). GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma. Journal for ImmunoTherapy of Cancer, 10(9), 1-15.
DOI Scopus79 WoS79 Europe PMC75
2021 Yeo, E. C. F., Brown, M. P., Gargett, T., & Ebert, L. M. (2021). The role of cytokines and chemokines in shaping the immune microenvironment of glioblastoma: implications for immunotherapy. Cells, 10(3, article no. 607), 1-25.
DOI Scopus59 WoS54 Europe PMC48
2021 Oksdath Mansilla, M., Salazar-Hernandez, C., Perrin, S. L., Scheer, K. G., Cildir, G., Toubia, J., . . . Gomez, G. A. (2021). 3D-printed microplate inserts for long term high-resolution imaging of live brain organoids. BMC biomedical engineering, 3(6), 1-14.
DOI Europe PMC17
2021 Lenin, S., Ponthier, E., Scheer, K. G., Yeo, E. C. F., Tea, M. N., Ebert, L. M., . . . Gomez, G. A. (2021). A drug screening pipeline using 2D and 3D patient-derived in vitro models for pre-clinical analysis of therapy response in glioblastoma. International Journal of Molecular Sciences, 22(9), 4322-1-4322-27.
DOI Scopus38 WoS37 Europe PMC35
2021 Truong, N. T. H., Gargett, T., Brown, M. P., & Ebert, L. M. (2021). Effects of chemotherapy agents on circulating leukocyte populations: potential implications for the success of car-t cell therapies. Cancers, 13(9, article no. 2225), 1-19.
DOI Scopus34 WoS30 Europe PMC25
2021 Martini, C., DeNichilo, M., King, D. P., Cockshell, M. P., Ebert, B., Dale, B., . . . Bonder, C. S. (2021). CD36 promotes vasculogenic mimicry in melanoma by mediating adhesion to the extracellular matrix. BMC Cancer, 21(1), 765-1-765-14.
DOI Scopus27 WoS26 Europe PMC22
2021 Brown, M. P., Ebert, L. M., & Gargett, T. (2021). Erratum: Clinical chimeric antigen receptor T-cell therapy: a new and promising treatment modality for glioblastoma.. Clinical & translational immunology, 10(8), e1331.
DOI Scopus1 WoS1 Europe PMC1
2020 Ebert, L. M., Yu, W., Gargett, T., Toubia, J., Kollis, P. M., Tea, M. N., . . . Brown, M. P. (2020). Endothelial, pericyte and tumor cell expression in glioblastoma identifies fibroblast activation protein (FAP) as an excellent target for immunotherapy. Clinical and Translational Immunology, 9(10), 1-24.
DOI Scopus52 WoS48 Europe PMC47
2020 Martini, C., Thompson, E. J., Hyslop, S. R., Cockshell, M. P., Dale, B. J., Ebert, L. M., . . . Bonder, C. S. (2020). Platelets disrupt vasculogenic mimicry by cancer cells. Scientific Reports, 10(1), 5869-1-5869-18.
DOI Scopus25 WoS21 Europe PMC20
2020 Zadeh Shirazi, A., Fornaciari, E., Bagherian, N. S., Ebert, L. M., Koszyca, B., & Gomez, G. A. (2020). DeepSurvNet: deep survival convolutional network for brain cancer survival rate classification based on histopathological images. Medical and Biological Engineering and Computing, 58(5), 1031-1045.
DOI Scopus52 WoS43 Europe PMC35
2019 Perrin, S. L., Samuel, M. S., Koszyca, B., Brown, M. P., Ebert, L. M., Oksdath, M., & Gomez, G. A. (2019). Glioblastoma heterogeneity and the tumour microenvironment: implications for preclinical research and development of new treatments. Biochemical Society Transactions, 47(2), 625-638.
DOI Scopus129 WoS122 Europe PMC108
2019 Gargett, T., TRUONG, N., EBERT, L., YU, W., & BROWN, M. (2019). Optimization of manufacturing conditions for chimeric antigen receptor T cells to favor cells with a central memory phenotype. Cytotherapy, 21(6), 593-602.
DOI Scopus32 WoS32 Europe PMC35
2019 Brown, M. P., Ebert, L. M., & Gargett, T. (2019). Clinical chimeric antigen receptor-T cell therapy: a new and promising treatment modality for glioblastoma. Clinical and translational immunology, 8(5, article no. e1050), 1-20.
DOI Scopus38 WoS36 Europe PMC33
2019 Gomez, G. A., Oksdath, M., Brown, M. P., & Ebert, L. M. (2019). New approaches to model glioblastoma in vitro using brain organoids: implications for precision oncology. Translational Cancer Research, 8(Suppl. 6), S606-S611.
DOI Scopus10 WoS10 Europe PMC12
2018 Ebert, L. M., Yu, W., Gargett, T., & Brown, M. P. (2018). Logic-gated approaches to extend the utility of chimeric antigen receptor T-cell technology. Biochemical Society Transactions, 46(2), 391-401.
DOI Scopus29 WoS28 Europe PMC23
2017 Davis, I. D., Quirk, J., Morris, L., Seddon, L., Tai, T. Y., Whitty, G., . . . Cebon, J. (2017). A pilot study of peripheral blood BDCA-1 (CD1c) positive dendritic cells pulsed with NY-ESO-1 ISCOMATRIX™ adjuvant. Immunotherapy, 9(3), 249-259.
DOI Scopus13 WoS14 Europe PMC12
2017 Tan, L. Y., Martini, C., Fridlender, Z. G., Bonder, C. S., Brown, M. P., & Ebert, L. M. (2017). Control of immune cell entry through the tumour vasculature: a missing link in optimising melanoma immunotherapy?. Clinical and Translational Immunology, 6(3), e134-1-e134-9.
DOI Scopus27 WoS28 Europe PMC25
2016 Ebert, L. M., Tan, L. Y., Johan, M. Z., Min, K. K. M., Cockshell, M. P., Parham, K. A., . . . Bonder, C. S. (2016). A non-canonical role for desmoglein-2 in endothelial cells: implications for neoangiogenesis. Angiogenesis, 19(4), 463-486.
DOI Scopus38 WoS39 Europe PMC31
2016 Tan, L., Mintoff, C., Johan, M., Ebert, B., Fedele, C., Zhang, Y., . . . Ebert, L. (2016). Desmoglein 2 promotes vasculogenic mimicry in melanoma and is associated with poor clinical outcome. Oncotarget, 7(29), 46492-46508.
DOI Scopus46 WoS46 Europe PMC42
2015 Pitman, M., Powell, J., Coolen, C., Moretti, P., Zebol, J., Pham, D., . . . Pitson, S. (2015). A selective ATP-competitive sphingosine kinase inhibitor demonstrates anti-cancer properties. Oncotarget, 6(9), 7065-7083.
DOI Scopus65 WoS64 Europe PMC56
2015 Moldenhauer, L., Cockshell, M., Frost, L., Parham, K., Tvorogov, D., Tan, L., . . . Bonder, C. (2015). Interleukin-3 greatly expands non-adherent endothelial forming cells with pro-angiogenic properties. Stem Cell Research, 14(3), 380-395.
DOI Scopus17 WoS18 Europe PMC14
2014 Tan, B., Anaka, M., Deb, S., Freyer, C., Ebert, L., Chueh, A., . . . Mariadason, J. (2014). FOXP3 over-expression inhibits melanoma tumorigenesis via effects on proliferation and apoptosis. Oncotarget, 5(1), 264-276.
DOI Scopus46 WoS42 Europe PMC37
2013 Bonder, C., & Ebert, L. (2013). Fos-icking for control of angiogenesis: Increasing the longevity of peritoneal dialysis. Kidney International, 84(6), 1065-1067.
DOI Scopus6 WoS6 Europe PMC6
2013 Klein, O., Ebert, L. M., Zanker, D., Woods, K., Tan, B. S., Fucikova, J., . . . Cebon, J. (2013). Flt3 ligand expands CD4⁺FoxP3⁺ regulatory T cells in human subjects. European Journal of Immunology, 43(2), 533-539.
DOI Scopus52 WoS52 Europe PMC47
2012 Ebert, L. M., MacRaild, S. E., Zanker, D., Davis, I. D., Cebon, J., & Chen, W. (2012). A cancer vaccine induces expansion of NY-ESO-1-specific regulatory T cells in patients with advanced melanoma. PLoS ONE, 7(10), e48424-1-e48424-10.
DOI Scopus54 WoS54 Europe PMC48
2012 Ebert, L. M., MacRaild, S. E., Davis, I. D., Cebon, J., & Chen, W. (2012). A novel method for detecting antigen-specific human regulatory T cells. Journal of Immunological Methods, 377(1-2), 56-61.
DOI Scopus5 WoS4 Europe PMC4
2010 Cebon, J., Knights, A., Ebert, L., Jackson, H., & Chen, W. (2010). Evaluation of cellular immune responses in cancer vaccine recipients: Lessons from NY-ESO-1. Expert Review of Vaccines, 9(6), 617-629.
DOI Scopus20 WoS18 Europe PMC17
2009 Klein, O., Ebert, L. M., Nicholaou, T., Browning, J., Russell, S. E., Zuber, M., . . . Cebon, J. (2009). Melan-a-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4. Clinical Cancer Research, 15(7), 2507-2513.
DOI Scopus93 WoS87 Europe PMC72
2009 Nicholaou, T., Ebert, L. M., Davis, I. D., McArthur, G. A., Jackson, H., Dimopoulos, N., . . . Cebon, J. (2009). Regulatory T-Cell-mediated attenuation of T-Cell responses to the NY-ESO-1ISCOMATRIX vaccine in patients with advanced malignant melanoma. Clinical Cancer Research, 15(6), 2166-2173.
DOI Scopus112 WoS101 Europe PMC94
2009 Ebert, L. M., Yu, C. L., Clements, C. S., Robson, N. C., Jackson, H. M., Markby, J. L., . . . Chen, W. (2009). A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: Implications for cancer vaccine design. Cancer Research, 69(3), 1046-1054.
DOI Scopus49 WoS45 Europe PMC38
2009 Dimopoulos, N., Jackson, H. M., Ebert, L., Guillaume, P., Luescher, I. F., Ritter, G., & Chen, W. (2009). Combining MHC tetramer and intracellular cytokine staining for CD8+ T cells to reveal antigenic epitopes naturally presented on tumor cells. Journal of Immunological Methods, 340(1), 90-94.
DOI Scopus15 WoS15 Europe PMC15
2009 Ebert, L. M., Liu, Y. C., Clements, C. S., Robson, N. C., Jackson, H. M., Markby, J. L., . . . Chen, W. (2009). A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: Implications for cancer vaccine design (Cancer Research (2009) 69, (1046-54)). Cancer Research, 69(10), 4553.
DOI
2008 Ebert, L. M., Bee, S. T., Browning, J., Svobodova, S., Russell, S. E., Kirkpatrick, N., . . . Chen, W. (2008). The regulatory T cell-associated transcription factor FoxP3 is expressed by tumor cells. Cancer Research, 68(8), 3001-3009.
DOI Scopus174 WoS154 Europe PMC142
2006 Schaerli, P., Ebert, L. M., & Moser, B. (2006). Comment on "The vast majority of CLA+ T cells are resident in normal skin" [1]. Journal of Immunology, 177(3), 1375-1376.
DOI Scopus5 WoS3 Europe PMC2
2006 Ebert, L. M., Meuter, S., & Moser, B. (2006). Homing and function of human skin γδ T cells and NK cells: Relevance for tumor surveillance. Journal of Immunology, 176(7), 4331-4336.
DOI Scopus218 WoS202 Europe PMC185
2006 Nicholaou, T., Ebert, L., Davis, I. D., Robson, N., Klein, O., Maraskovsky, E., . . . Cebon, J. (2006). Directions in the immune targeting of cancer: Lessons learned from the cancer-testis Ag NY-ESO-1. Immunology and Cell Biology, 84(3), 303-317.
DOI Scopus101 WoS94 Europe PMC82
2005 Schaerli, P., Willimann, K., Ebert, L. M., Walz, A., & Moser, B. (2005). Cutaneous CXCL14 targets blood precursors to epidermal niches for langerhans cell differentiation. Immunity, 23(3), 331-342.
DOI Scopus126 WoS114 Europe PMC108
2004 Ebert, L. M., Horn, M. P., Lang, A. B., & Moser, B. (2004). B cells alter the phenotype and function of follicular-homing CXCR5+ T cells. European Journal of Immunology, 34(12), 3562-3571.
DOI Scopus36 WoS33 Europe PMC33
2004 Schaerli, P., Ebert, L., Willimann, K., Blaser, A., Roos, R. S., Loetscher, P., & Moser, B. (2004). A Skin-selective Homing Mechanism for Human Immune Surveillance T Cells. Journal of Experimental Medicine, 199(9), 1265-1275.
DOI Scopus193 WoS174 Europe PMC156
2002 Ebert, L., & McColl, S. (2002). Up-regulation of CCR5 and CCR6 on distinct subpopulations of antigen-activated CD4⁺ T lymphocytes. Journal of Immunology, 168(1), 65-72.
DOI Scopus72 WoS70 Europe PMC66
2001 Ebert, L., & McColl, S. (2001). Coregulation of CXC chemokine receptor and CD4 expression on T lymphocytes during allogeneic activation. Journal of Immunology, 166(8), 4870-4878.
DOI Scopus41 WoS35 Europe PMC27
1999 Gale, L., & McColl, S. (1999). Chemokines: extracellular messengers for all occasions?. Bioessays, 21(1), 17-28.
DOI Scopus113 WoS108 Europe PMC94

Year Citation
2023 Shard, C., Ormsby, R., Poonnoose, S., Toubia, J., Trim, P., Ebert, L., . . . Gomez, G. (2023). INVESTIGATING HOW GLIOBLASTOMA TUMOUR CELLS EXPLOIT THEIR METABOLIC MICROENVIRONMENT. In NEURO-ONCOLOGY Vol. 25 (pp. 1 page). CANADA, Vancouver: OXFORD UNIV PRESS INC.
2005 Ebert, L. M., Schaerli, P., & Moser, B. (2005). Chemokine-mediated control of T cell traffic in lymphoid and peripheral tissues. In Molecular Immunology Vol. 42 (pp. 799-809). CANADA, Quebec City: PERGAMON-ELSEVIER SCIENCE LTD.
DOI Scopus251 WoS227 Europe PMC215
2003 Moser, B., & Ebert, L. (2003). Lymphocyte traffic control by chemokines: Follicular B helper T cells. In Immunology Letters Vol. 85 (pp. 105-112). DENMARK, ELSIMORE: ELSEVIER.
DOI Scopus46 WoS38 Europe PMC36

Year Citation
2024 Toomes, C., McClure, B., Best, G., Ebert, L., Vandyke, K., Cockshell, M., . . . Bonder, C. (2024). Elevated Desmoglein-2 Surface Expression Is an Independent Predictor of Poor Outcome in Multiple Myeloma. Poster session presented at the meeting of CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. CIG MEDIA GROUP, LP.

Year Citation
2025 Gardam, B., Nam, E., Kollis, P. M., Kilyen-Coles, J., Lenin, S., Gliddon, B. L., . . . Gargett, T. (2025). A Characterization of the Immune Cells in Immunocompetent and Immunodeficient Mice with Orthotopic Brain Tumors.
DOI Europe PMC1
2025 Gardam, B., Gargett, T., Nam, E., Khan, S., Ormsby, R. J., Poonnoose, S. I., . . . Ebert, L. M. (2025). Tumors Located in the Brain Impair the Frequency and Phenotype of Dendritic Cells in Blood and Tumor.
DOI
2023 Yu, W., Truong, N. T. H., Polara, R., Gargett, T., Tea, M., Pitson, S., . . . Brown, M. (2023). Endogenous bystander killing mechanisms enhance the activity of novel FAP-specific CAR-T cells against glioblastoma.
DOI

  • Enhancing the entry of therapeutic CAR-T cells into brain tumours, Neurosurgical Research Foundation, 01/08/2025 - 30/01/2027

  • Investigating dual targeting GD2 and FAP CAR T-cells for the treatment of brain malignancies, Neurosurgical Research Foundation, 01/10/2025 - 30/09/2026

  • Targeting tumour ecosystem interactions to overcome glioblastoma therapeutic resistance, Neurosurgical Research Foundation, 01/10/2025 - 30/09/2026

  • Defining the therapeutic potential of eosinophils in melanoma, Australian Melanoma Research Foundation, 01/02/2025 - 31/07/2026

  • Exploiting blood vessels as conduits for the entry of therapeutic CAR-T cells into brain tumours, Neurosurgical Research Foundation, 02/10/2023 - 31/10/2025

  • Desmoglein-2; an unsuspected regulator of melanoma, NHMRC - Project Grant, 01/01/2019 - 31/12/2022

  • Development of a new therapy for glioblastoma based on chimeric antigen receptor (CAR)-T cells, Tour de Cure Ltd, 01/01/2021 - 31/12/2022

  • Validation of a novel therapeutic target in multiple myeloma, Royal Adelaide Hospital, 01/01/2016 - 31/03/2017

  • Checkpoint blockade immunotherapy in melanoma: getting tumour-killing T cells to their site of action, Royal Adelaide Hospital, 01/01/2016 - 31/03/2017

Date Role Research Topic Program Degree Type Student Load Student Name
2025 Co-Supervisor To identify biomarkers of patient response to CAR-T cell therapy Doctor of Philosophy Doctorate Full Time Mr Ryan U Theen Chin
2025 Principal Supervisor Pre-clinical development of FAP-targeting CAR-T cells for the treatment of Glioblastoma. Doctor of Philosophy Doctorate Full Time Miss Jasmine Elizabeth Kilyen-Coles
2025 Co-Supervisor To identify biomarkers of patient response to CAR-T cell therapy Doctor of Philosophy Doctorate Full Time Mr Ryan U Theen Chin
2025 Co-Supervisor A bioengineered "brain tumour on a chip" recapitulating treatment resistance towards precision radiotherapy with nanoparticulate radiosensitisers Doctor of Philosophy Doctorate Full Time Ms Esmee Broekhuizen
2025 Principal Supervisor Pre-clinical development of FAP-targeting CAR-T cells for the treatment of Glioblastoma. Doctor of Philosophy Doctorate Full Time Miss Jasmine Elizabeth Kilyen-Coles
2024 Co-Supervisor Investigating dual targeting CAR-T cells for the treatment of brain tumours Doctor of Philosophy Doctorate Full Time Miss Abbey Rose Marshall
2024 Co-Supervisor Investigating dual targeting CAR-T cells for the treatment of brain tumours Doctor of Philosophy Doctorate Full Time Miss Abbey Rose Marshall
2023 Principal Supervisor Investigating the Dendritic Cell - T Cell Axis in Glioblastoma to Explore New Combination Immunotherapy Treatment Options Doctor of Philosophy Doctorate Full Time Mr Bryan Gardam
2023 Principal Supervisor Investigating the Dendritic Cell - T Cell Axis in Glioblastoma to Explore New Combination Immunotherapy Treatment Options Doctor of Philosophy Doctorate Full Time Mr Bryan Gardam
2023 Principal Supervisor Enhancing cancer immunotherapy success by efficient recruitment of T cells to solid tumours Doctor of Philosophy Doctorate Full Time Resty Nabeeta
2023 Co-Supervisor 110496 - Lipid-based Nanocarrier Enabled Delivery for Improved T-cell Immunotherapy Doctor of Philosophy Doctorate Full Time Miss Isabella Ampelia Revesz
2022 Principal Supervisor Identifying optimal immunotherapy combinations for the treatment of brain tumours Doctor of Philosophy Doctorate Full Time Mr Chris Nam
2021 Co-Supervisor Tumour protein D54 as a regulator of melanoma progression Doctor of Philosophy Doctorate Full Time Mr Michael Ortiz
2020 Co-Supervisor Targeting cancer cell invasion for new personalised therapeutic approaches against glioblastoma Doctor of Philosophy Doctorate Full Time Miss Sally Perrin

Connect With Me

External Profiles

Other Links